JP2024540402A5 - - Google Patents
Info
- Publication number
- JP2024540402A5 JP2024540402A5 JP2024527084A JP2024527084A JP2024540402A5 JP 2024540402 A5 JP2024540402 A5 JP 2024540402A5 JP 2024527084 A JP2024527084 A JP 2024527084A JP 2024527084 A JP2024527084 A JP 2024527084A JP 2024540402 A5 JP2024540402 A5 JP 2024540402A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- structural formula
- immune complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275177P | 2021-11-03 | 2021-11-03 | |
| US63/275,177 | 2021-11-03 | ||
| US202163295476P | 2021-12-30 | 2021-12-30 | |
| US63/295,476 | 2021-12-30 | ||
| PCT/US2022/048735 WO2023081230A1 (en) | 2021-11-03 | 2022-11-02 | Novel auristatin analogs and immunoconjugates thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540402A JP2024540402A (ja) | 2024-10-31 |
| JP2024540402A5 true JP2024540402A5 (enExample) | 2025-11-12 |
Family
ID=86241915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527084A Pending JP2024540402A (ja) | 2021-11-03 | 2022-11-02 | 新規オーリスタチン類似体およびその免疫複合体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20260131016A1 (enExample) |
| EP (1) | EP4426714A4 (enExample) |
| JP (1) | JP2024540402A (enExample) |
| KR (1) | KR20240110584A (enExample) |
| AU (1) | AU2022380491A1 (enExample) |
| CA (1) | CA3236944A1 (enExample) |
| IL (1) | IL312533A (enExample) |
| MX (1) | MX2024005342A (enExample) |
| TW (1) | TW202334176A (enExample) |
| WO (1) | WO2023081230A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4786483A1 (en) | 2023-09-26 | 2026-08-05 | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. | Auristatin derivative and antibody-drug conjugate thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2605443T3 (es) * | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| US20130190248A1 (en) * | 2011-07-26 | 2013-07-25 | Agensys, Inc. | Substituted peptide analogs |
| US20130280282A1 (en) * | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
| AR097161A1 (es) * | 2013-08-01 | 2016-02-24 | Agensys Inc | Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37 |
| PL3204425T3 (pl) * | 2014-10-09 | 2021-03-08 | Genzyme Corporation | Glikomodyfikowane koniugaty przeciwciał z lekami |
| US20170014524A1 (en) * | 2015-07-15 | 2017-01-19 | The California Institute For Biomedical Research | Auristatin-antibody conjugates and uses thereof |
-
2022
- 2022-11-02 JP JP2024527084A patent/JP2024540402A/ja active Pending
- 2022-11-02 US US18/704,394 patent/US20260131016A1/en active Pending
- 2022-11-02 EP EP22890732.5A patent/EP4426714A4/en active Pending
- 2022-11-02 WO PCT/US2022/048735 patent/WO2023081230A1/en not_active Ceased
- 2022-11-02 KR KR1020247017701A patent/KR20240110584A/ko active Pending
- 2022-11-02 MX MX2024005342A patent/MX2024005342A/es unknown
- 2022-11-02 IL IL312533A patent/IL312533A/en unknown
- 2022-11-02 AU AU2022380491A patent/AU2022380491A1/en active Pending
- 2022-11-02 CA CA3236944A patent/CA3236944A1/en active Pending
- 2022-11-03 TW TW111142076A patent/TW202334176A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102486055B1 (ko) | 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법 | |
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| JP2025509286A5 (enExample) | ||
| JP2021527040A5 (enExample) | ||
| JP2022087255A (ja) | キャリア結合剤組成物およびそれを作製および使用する方法 | |
| JP7465347B2 (ja) | 抗ｃ－Ｍｅｔ抗体薬物複合体 | |
| JP2021121590A5 (enExample) | ||
| TW202010498A (zh) | 喜樹鹼肽結合物 | |
| JP2021512865A5 (enExample) | ||
| JP2022512643A5 (enExample) | ||
| JP2009501800A5 (enExample) | ||
| WO2024227439A1 (zh) | 具有靶向作用的偶联物及其制备方法和用途 | |
| TWI558399B (zh) | 癌症之組合療法 | |
| JP2023529640A (ja) | 治療用コンジュゲート | |
| NL2020121B1 (en) | Platinum-based functional moieties for preparing cell targeting conjugates | |
| JP2023512227A5 (enExample) | ||
| JP2025500404A5 (enExample) | ||
| JP2023512206A5 (enExample) | ||
| JPH07223969A (ja) | チオエーテル結合体の製造法 | |
| JP2020534326A (ja) | イムノコンジュゲートにおけるメチオニン酸化を防止する方法 | |
| JP2023512228A5 (enExample) | ||
| CN108653746B (zh) | 一种多载药点、高载药配基药物偶联物 | |
| JP2023546293A5 (enExample) | ||
| JPWO2022154127A5 (enExample) | ||
| JP2023512229A5 (enExample) |